ArticleToxicology reports2025
Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- UA mitigates cisplatin-induced toxicity suggesting involvement of the KEAP1-NRF2 pathway: insights from histopathological validation, molecular docking, and molecular dynamics.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arsenic is a toxic metalloid that can lead to oxidative stress in cells by inducing reactive oxygen species (ROS) and interfering with cellular antioxidant defenses. Thioredoxin interacting protein (TXNIP) is an important regulator of redox processes. Activation and upregulation of TXNIP may play a central role in the mechanisms underlying arsenic-induced oxidative stress, inflammation, and cytotoxicity. Arsenic exposure has been shown to upregulate TXNIP expression, further amplifying oxidative stress, causes cellular damage. In the present study, the antioxidant potential of 50 phytochemicals from S. aromaticum and T. chebula, were screened using molecular docking studies against TXNIP, followed by MD simulations studies. The study revealed stigmasterol to exhibit the highest negative dock score and hence best binding affinity towards the target protein (TXNIP). The minimum binding energy of -10.14 Kcal/mol as compared to the fisetin with a binding energy of -7.15 Kcal/mol, the latter being selected as one of the standard drugs for our study. The MD simulation study of the stigmasterol-TXNIP complex for 100 Nanoseconds exhibited a stable interaction between protein-ligand thus validating our docking studies. The study also involved in vitro analysis of the best inhibitor of TXNIP uncovered in molecular docking studies. The in-vitro analysis demonstrated that stigmasterol pre-treatment conferred significant protection against Sodium Arsenite-mediated cytotoxicity in cultured Vero cells (African green monkey kidney cells). Furthermore, we employed 2'-7'-Dichlorodihydrofluorescein diacetate staining and captured fluorescent images, fluorescence images provided visual evidence supporting the cytoprotective role of stigmasterol, as evidenced by a reduction in oxidative stress compared to arsenic-treated cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.